VISION 2027
Bridging Clinical Signals to Digital — Transforming pain tracking, structural questionnaires, and vital signs into actionable data parameters to power a next-generation digital healthcare ecosystem.
*Estimated FY2025 Medicare Advantage federal expenditures/payments: approximately $500B. This figure is not CyberMDCare's addressable revenue, reimbursement opportunity, market share, or guaranteed commercial opportunity.
Our Vision
The Future We Envision
A preventive model of care where clinical insights are collected and synthesized in real time—may help clinicians review patient-reported and device-generated information earlier and support appropriate follow-up, subject to clinical validation and implementation. CyberMDCare is anchoring the future of virtual medicine.
Problem Statement
The Problem We Solve
The U.S. Medicare Advantage market is estimated at approximately $500 billion in federal expenditures annually. Yet as virtual care expands, consistently capturing clinical data and reliably verifying patient identity remain unresolved challenges.
The Data Gap
CMS has been phasing in the V28 HCC risk-adjustment model since 2024. This model demands robust clinical evidence, yet systematically accumulating such data in a fragmented telehealth environment remains a significant challenge.
The Trust Gap
In virtual care settings, verifying that the person receiving treatment is the actual insurance beneficiary is structurally difficult — a challenge addressing identity-assurance and program-integrity risks that may arise in virtual care.
CyberMDCare aims to address both gaps head-on through clinical data processing technology and biometric authentication.
※ Market size figures are reference estimates based on CMS FY2025 Medicare Advantage expenditure reports and do not guarantee any revenue or profit of the Company.
Core Technology
Core Technology Framework
An advanced algorithmic framework designed to unify heterogeneous health vectors—specifically Pain coordinates, variable Questionnaires, and Respiratory/Vital Signs—into a single, standardized clinical signal stream for streamlined processing.
An optimized software engine—clinicalEvidenceEngine.ts—engineered to process multiple streams of clinical data concurrently. AI-enabled tools are intended to support healthcare providers' review and workflow efficiency. They are not a substitute for professional medical judgment, diagnosis, or treatment.
BioSignBox is intended to use biometric templates and session metadata only as necessary for identity assurance, with clear notice, applicable consent or authorization where required, retention limits, encryption, role-based access controls, audit logs, and applicable Business Associate Agreements.
Data from compatible devices and mobile endpoints is intended to be encrypted in transit and at rest and stored in a HIPAA-supportive cloud environment, with role-based access controls, audit logging, risk analysis, and applicable Business Associate Agreements. HIPAA compliance depends on the final deployment, configuration, policies, and legal relationships.
Integration Strategy
clinicalEvidenceEngine.ts & CMS-HCC Risk-Adjustment Documentation Support Strategy
Patient input & measurements → secure transmission → encrypted storage → access by authorized clinical users through role-based permissions, authentication, and audit logs → clinician review and, where appropriate, clinical follow-up.
Our P·Q·R signal system is intended to support clinician documentation and care-management workflows relevant to Medicare Advantage risk adjustment. It does not generate diagnoses or determine HCC codes; any HCC coding or submission must be based on clinician-validated diagnoses and compliant medical record documentation.
The CMS-HCC model is used as part of the Medicare Advantage risk-adjustment methodology. Payments are subject to CMS methodology, eligible diagnoses, encounter data, plan submissions, normalization, coding-intensity adjustments, and audits. P·Q·R data may support clinician review and documentation workflows that can be relevant to risk-adjustment coding. HCC code capture or submission must be based on independently validated clinician diagnoses, applicable ICD-10-CM coding guidance, and compliant medical record documentation.
AWV-related data collection does not itself constitute furnishing or billing an Annual Wellness Visit. Providers remain responsible for CMS coverage, documentation, patient eligibility, telehealth, and billing requirements.
※ Currently in development and technical validation stage. Deployment in clinical settings requires compliance with U.S. federal and state regulations, clinical validation, and partnership agreements.
Identity Verification
BioSignBox — Supporting Trust and Identity Assurance in Virtual Care
One of the most critical challenges arising from the expansion of virtual care is the vulnerability of patient identity verification. BioSignBox is our dual-biometric signature technology currently under development to address this challenge proactively.
BioSignBox is intended to use biometric templates and session metadata only as necessary for identity assurance, with clear notice, applicable consent or authorization where required, retention limits, encryption, role-based access controls, audit logs, and applicable Business Associate Agreements.
The technology is intended to support identity assurance and provide an auditable record for patient consent or authorization workflows. It does not by itself determine the legal validity of consent; validity depends on the applicable form, workflow, federal and state law, and provider policies.
Given the U.S. medical litigation environment and regulatory audit risks, this capability aims to serve as a meaningful risk management tool for medical institutions.
Development Status: BioSignBox is currently under active development and has not yet been commercialized. This technology has been filed as a Provisional Patent Application with the USPTO (United States Patent and Trademark Office). The scope of patent protection will be determined upon conversion to a non-provisional application and completion of the USPTO examination process.
Roadmap
The Road to 2027
Technology Foundation & Priority Date Establishment
Implement the core technology architecture — including the P·Q·R clinical engine and BioSignBox — and file 18 Provisional Patent Applications with the USPTO to establish priority dates across the full technology ecosystem.
Non-Provisional Conversion & Field Validation
Convert each provisional filing to a non-provisional application within 12 months and advance USPTO examination. Concurrently, conduct technology compatibility reviews and preliminary partnership discussions with U.S. medical groups (MSOs and IPAs).
Global Digital Healthcare Ecosystem
Expand a fully integrated digital healthcare ecosystem connecting mobile, cloud, and AI. The focus is intended to support access to care for Medicare patients with chronic conditions.
Intellectual Property
Intellectual Property Status
CyberMDCare has filed a total of 18 Provisional Patent Applications with the USPTO to protect its core technologies.
Clinical Data Processing — P (Pain coordinates) · Q (Variable questionnaire) · R (Vital signs) integrated algorithm
Clinical Evidence Engine — clinicalEvidenceEngine.ts real-time digital signal processing
Biometric Signature System — BioSignBox dual biometric signature + behavioral log binding
Cloud Integration Architecture — Bluetooth medical device & mobile real-time data collection and storage
Company
Company Information
*CyberMDCare is an independent technology company and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any Medicare Advantage plan unless expressly stated.
Connecting People to Longer, Healthier Lives Through Technology
Helping every person live longer and healthier — by elevating both the speed and precision of medicine. CyberMDCare is forging that path through a clinical evidence-based digital healthcare technology system.
Longer and Healthier LivesLegal
Investor Notices & Forward-Looking Statement Disclaimer
This page contains forward-looking statements regarding CyberMDCare's technology development, business plans, market outlook, and patent filing strategy. Such statements are based on current assumptions, plans, expectations, and estimates.
1. Forward-Looking Statements
2. Basis and Assumptions
3. Risk of Differing Outcomes
4. Special Notice Regarding Provisional Patent Applications
5. Corporate Disclosure
This disclaimer has been prepared with reference to the Safe Harbor provisions of Article 125, Paragraph 2 of the Republic of Korea Financial Investment Services and Capital Markets Act.